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Abstract
 
Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease of
the lungs with little or no response to glucocorticoids and a high level of oxidative stress. Histone
deacetylase (HDAC) activity is reduced in cells of cigarette smokers, and low concentrations of
theophylline can increase HDAC activity. We measured the effect of theophylline on HDAC
activity and inflammatory gene expression in alveolar macrophages (AM) from patients with
COPD. AM from normal smokers showed a decrease in HDAC activity compared with normal
control subjects, and this was further reduced in COPD patients (51% decrease, P 
 
 
 
0.01).
COPD AMs also showed increased basal release of IL-8 and TNF-
 

 
, which was poorly suppressed
by dexamethasone. Theophylline induced a sixfold increase in HDAC activity in COPD AM
lysates and significantly enhanced dexamethasone suppression of induced IL-8 release, an effect
that was blocked by the HDAC inhibitor trichostatin A. Therefore, theophylline might restore
steroid responsiveness in COPD patients.
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Introduction
 
Chronic obstructive pulmonary disease (COPD) is a common
and debilitating chronic inflammatory disease characterized
by progressive airflow limitation that is poorly reversible (1).
Cigarette smoking is the major causal factor for the ongoing
inflammation in the airways and lung parenchyma, and the
severity of airflow limitation is correlated with degree of pul-
monary inflammation (2). Inflammation is amplified in the
lungs of COPD patients with a striking increase in macro-
phage numbers as the disease becomes more severe (3). In
addition, neutrophil chemotactic mediators, such as IL-8 and
proinflammatory cytokines, such as TNF-
 

 
, are increased in
the sputum of patients with COPD (4). Importantly, the in-
flammation in COPD is unresponsive to corticosteroids.
Even high doses of inhaled and oral glucocorticoids have no
effect on the inflammatory cell and cytokine profile and fail
to reverse the protease-antiprotease imbalance (5). Further-
more, the antiinflammatory response to glucocorticoids is
reduced in alveolar macrophages (AM) from normal smokers
compared with nonsmokers and is absent in cells from pa-
tients with COPD (6).
Histone acetytransferases (HAT) and histone deacetylase
(HDAC) are families of enzymes that regulate chromatin
structure and thereby affect inflammatory gene expression
(7). Acetylation of core histones by coactivator proteins
that possess intrinsic HAT activity leads to unwinding of
chromatin, which subsequently allows transcription factors
and RNA polymerase II to switch on gene transcription.
Conversely, deacetylation of core histones is generally asso-
ciated with transcriptional repression. We have shown pre-
viously that glucocorticoid suppression of inflammatory
genes requires recruitment of HDAC2 to the transcrip-
tional activation complex by the glucocorticoid receptor
(GR) (8).
The lack of response to glucocorticoids may be second-
ary to the increased oxidative stress as a result of cigarette
smoking (9) leading to reduced HDAC activity (10). The-
ophylline is a bronchodilator at high doses; however, there
is increasing evidence that at lower concentrations it has
antiinflammatory effects in asthma and COPD (11), possi-
bly due to an effect on HDAC activity, resulting in sup-
pression of inflammatory genes and enhancement of the
antiinflammatory effects of glucocorticoids (12). We inves-
tigated the effect of theophylline on HDAC activity and
glucocorticoid antiinflammatory action in alveolar macro-
phages from COPD patients.
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Materials and Methods
 
Patients.
 
19 patients with COPD diagnosed according to
GOLD guidelines 
 
(13)
 
, 15 current smokers without airway ob-
struction (FEV
 
1
 
 of 
 

 
70% predicted), and 13 nonsmokers with
normal lung function were recruited. All patients studied under-
went elective bronchoscopy for diagnostic purposes, and normal
subjects were volunteers recruited through advertisement. Sub-
jects with COPD and smokers both had a smoking history of
 

 
20 packs per year. COPD subjects receiving inhaled corticoster-
oids or oral theophylline and those with an acute exacerbation
in the previous 6 wk were excluded. Exclusion criteria for smok-
ers and nonsmokers were suspicion of infective or interstitial dis-
ease, age 
 

 
35 yr. The study was approved by the Ethics Com-
mittees of the Harefield and Royal Brompton, St Mary’s and
Riverside Hospital NHS Trusts, and all the subjects gave their
signed consent.
After initial recruitment, six patients in the COPD group,
three patients in the smoker group, and one patient in the non-
smoking group were excluded. The reasons for exclusion were:
infection of the cultured macrophages (4) and insufficient macro-
phage yield (6). Data from all the remaining subjects are included
(Table I). There were significant differences in the number of
macrophages and neutrophils in smokers and COPD patients
compared with nonsmokers (Table I).
 
Bronchoscopy and Bronchoalveolar Lavage.
 
Bronchoscopy and
bronchoalveolar lavage (BAL) was collected according to a stan-
dard protocol from the right middle lobe or the contralateral lobe
to pathology as previously described (10).
 
Isolation and Culture of AM.
 
BAL cells were centrifuged (500 
 
g
 
for 10 min) and washed twice with Hanks buffered salt solution.
Cell viability was assessed by trypan blue exclusion, and cytospins
were prepared as described previously (10). BAL macrophages
were either lysed or isolated by plastic adhesion as previously de-
scribed (10), and cells (3 
 

 
 10
 
5
 
) were incubated in 24-well plates
in the presence of theophylline (10 
 

 
M), dexamethasone (1 
 

 
M),
and/or 
 
Salmonella enteritidis
 
 LPS (10 
 

 
g/ml; Sigma-Aldrich).
 
U937 Cell Culture.
 
Cells were cultured exactly as described
previously (10).
 
Cytokine ELISAs.
 
IL-8 and TNF-
 

 
 concentrations were de-
termined by sandwich ELISA according to the manufacturer’s in-
structions (R&D Systems Europe).
 
Glutathione Assay.
 
Total glutathione was determined in BAL
fluid using a colorimetric assay kit (Oxford Biomedical Research)
according to the manufacturer’s instructions.
 
Western Blotting.
 
Nuclear extracts were measured by Western
blotting using specific antibodies obtained from Santa Cruz Bio-
technology as previously described (8).
 
HDAC Activity.
 
HDAC activity of nuclear extracts was mea-
sured with a nonisotopic assay (BIOMOL) as recommended by the
manufacturer. Specific HDAC isoforms were immunoprecipitated
before analysis of HDAC activity as described previously (8).
 
Immunocytochemistry.
 
Cytospins were stained using antibod-
ies against HDAC2 and p65 subunit of NF-
 

 
B (Santa Cruz Bio-
technology). All antibodies were used at dilutions of 1:50–1:200
of a 200 mg/ml solution. Bronchial biopsies were used as control.
For the negative control slides, normal rabbit nonspecific immu-
noglobulins (Dako) were used.
 
Statistics.
 
Results are expressed as means 
 

 
 SEM. Changes in
AM secretory products were compared with control subjects using
analysis of variance (ANOVA). Comparison between experimental
groups was performed using the Mann-Whitney U test. All statisti-
cal testing was performed at a two-sided 5% level of significance
using GraphPad Prism software (GraphPad Software Inc.).
 
Results and Discussion
 
Patients with COPD showed significantly higher levels of
IL-8 and glutathione in BAL fluid than smokers and non-
smokers (Table I). Baseline secretion of IL-8 was increased in
AM from smokers and COPD patients compared with nor-
 
Table I.
 
 Patient Characteristics and BAL Fluid Measurements
 
COPD 
(
 
n
 
 
 
 
 
13)
Smokers 
(
 
n
 
 
 
 
 
12)
Nonsmokers 
(
 
n
 
 
 
 
 
12)
Age (yr) 69.4 
 
 
 
2.6 64.2 
 
 
 
3.5 62.2 
 
 
 
4.4
Sex (male:female) 7:7 9:3 6:6
FEV1 (L) 1 .15 
 
 
 
0.13
 
a
 
2.67 
 
 
 
0.1 3.27 
 
 
 
0.3
FEV1 (% predicted) 49.8 
 
 
 
3.3
 
a
 
83 
 
 
 
1.6 91.8 
 
 
 
7.5
FEV
 
1
 
:FVC ratio 0.59 
 
 
 
0.06
 
c
 
0.70 
 
 
 
0.02 0.74 
 
 
 
0.03
Pack-years 39 
 
 
 
4 48 
 
 
 
9 0
Diagnosis: cancer 7 7 2
Volume of BAL recovered (ml) 42.5 
 
 
 
5 46 
 
 
 
8.8 57 
 
 
 
9.3
Macrophages (
 

 
10
 
3
 
/ml) BAL fluid recovered 204.9 
 
 
 
35
 
c
 
220.4 
 
 
 
39
 
c
 
101.1 
 
 
 
25
Macrophages (%) 88.9 
 
 
 
0.9 91.2 
 
 
 
0.8 93 
 
 
 
0.4
Neutrophils (%) 4.1 
 
 
 
0.3
 
c
 
3.9 
 
 
 
0.6 2.8 
 
 
 
0.5
IL-8 (pg/
 

 
g protein) 3.4 
 
 
 
0.7
 
b
 
1.2 
 
 
 
0.5
 
c
 
0.40 
 
 
 
0.3
Glutathione (
 

 
M/
 

 
g protein) 0.36 
 
 
 
0.03
 
b
 
0.15 
 
 
 
0.02 0.12 
 
 
 
0.03
FEV
 
1
 
, forced expiratory volume in 1 s; FVC, forced vital capacity; BAL, bronchoalveolar lavage.
Significance of difference compared to nonsmokers: 
 
a
 
P
 
  
 
0.001, 
 
b
 
P
 
  
 
0.01, 
 
c
 
P
 
  
 
0.05.
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mal (P 
 
 
 
0.05 versus normal) and increased significantly
more in AM from smokers and COPD patients after LPS
stimulation (P 
 
 
 
0.05 versus normal) (Fig. 1 A). The NF-
 

 
B
inhibitor AS602868 inhibited LPS-induced IL-8 production
by 76% (14.0 
 

 
 1.2 versus 58.7 
 

 
 0.9 ng/ml, P 
 
 
 
0.01).
Dexamethasone was less effective in reducing IL-8 and
TNF-
 

 
 release in COPD patients and smokers compared
with controls (Fig. 1, A and B). Using immunocytochemis-
try (not depicted) and Western blotting of nuclear extracts
from AM, we confirmed that there was enhanced nuclear
translocation of the p65 subunit of NF-
 

 
B in COPD pa-
tients compared with normal subjects (0.38 
 

 
 0.06 versus
0.11 
 

 
 0.01 arbitrary units, P 
 
 
 
0.05) and to a lesser extent
also in smokers (0.25 
 

 
 0.05, P 
 
 
 
0.05).
HDAC activity was significantly reduced in AM from
COPD patients (2788 
 

 
 339 AFU/10 
 

 
g) compared with
smokers (3562 
 

 
 392 AFU/10 
 

 
g, P 
 
 
 
0.05) and normal
subjects (5664 
 

 
 521 AFU/10 
 

 
g, P 
 
 
 
0.01) (Fig. 2 A).
This correlated with a reduction in HDAC2 protein ex-
pression observed by immunocytochemistry (Fig. 2 B) and
Western blotting (2.1 
 

 
 0.1 versus 1.4 
 

 
 0.2 versus 1.0 
 

 
0.1 ratio to 
 
	-actin expression) (Fig. 2 C).
We have reported previously in cell lines that theophyl-
line enhances HDAC activity (12). Therefore, we exam-
ined whether we could detect the same phenomena in AM
from smokers and patients with COPD. Nuclear extracts
from COPD and smokers directly exposed to theophylline
Figure 1. Effect of dexamethasone on cytokine release from AM. AM
from normal subjects, healthy smokers, and patients with COPD were in-
cubated with dexamethasone (Dex; 10
6 M) for 30 min before being
stimulated with LPS (10 g/ml). LPS-induced IL-8 release (A) and
TNF release (B) after 18 h were measured. *P  0.05 versus control
subjects; #P  0.05 versus unstimulated cells; ¶P  0.05 versus LPS-
stimulated cells; n  6 in each group.
Figure 2. HDAC activity and expression in AM. (A) HDAC activity
was measured in protein extracts from AM obtained from normal sub-
jects, healthy smokers, and COPD patients and expressed according to
protein content. ##P  0.01 versus nonsmoker; *P  0.05 versus smoker;
n  6 in each group. (B) Immunocytochemical analysis of HDAC2 ex-
pression in AM from normal subjects and patients with COPD. Results
are representative of at least six subjects in each group. (C) Western blot
analysis of HDAC2 expression in AM from normal subjects, healthy
smokers, and COPD patients and expressed according to protein content.
*P  0.05 versus nonsmoker, n  3 in each group.
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(10
5 and 10
6 M) showed an approximate sixfold increase
in HDAC activity (16,015  509 versus 2,788  339
AFU/10 g, P  0.001) (Fig. 3 A). Functionally, in cul-
tured AM obtained from COPD patients, theophylline
(10
6 M) alone had no effect on LPS-stimulated IL-8 re-
lease. In contrast, high concentrations of dexamethasone
(10
6 M) partially suppressed LPS-stimulated IL-8 release
by 36% (117  11 ng/ml versus 184  19 ng/ml, P 
0.05). Co-incubation of theophylline (10
6 M) and dexa-
methasone (10
6 M) enhanced the suppressive effect of
dexamethasone on LPS-stimulated IL-8 release (64  10
versus 184  19 ng/ml, P  0.01) (Fig. 3 B). This effect
was significantly greater than that seen with dexametha-
sone (1 M) alone.
Due to the lack of AM available from patients, we used
PMA-treated U937 cells as a macrophage cell model to
further study the interactions between glucocorticoids and
theophylline since we have shown similar effects of theo-
phylline in this cell line to those now reported in primary
cells. After preincubation of these cells with hydrogen per-
oxide (H2O2, 100 M) for 4 h, there was a marked in-
crease in IL-1	–stimulated IL-8 release (2.41  0.18 versus
1.88  0.38 ng/ml, P  0.05) and a reduced ability of dex-
amethasone (10
8 M) to suppress IL-8 release, thus mim-
icking the situation in COPD macrophages (Fig. 4 A). This
was also reflected in the dexamethasone IC50 (IL-1	 6.6 
0.4 nM versus IL-1	  H2O2  1 M, P  0.01) and was
accompanied by a marked decrease in HDAC activity in
these cells after H2O2 (100 M) treatment (46  3 versus
130  8 AFU/g protein, P  0.01). This effect of H2O2
was completely blocked by 10 mM N-acetyl cysteine
(basal; 182  24 versus H2O2; 52  13 versus H2O2 
NAC; 163  45 versus AFU/g protein, P  0.01). Simi-
lar effects on HDAC activity were also seen with cigarette
smoke extract (Fig. 4 B) and resulted in enhanced IL-8 re-
lease (1.36  0.24 versus 0.28  0.04 ng/ml IL-8). This
was completely blocked by addition of 10 mM NAC
(0.34  0.08 versus 1.36  0.24 ng/ml). Addition of the-
ophylline (10
6 M) alone had a small effect on IL-1	–stimu-
lated IL-8 release (1.24  0.07 versus 1.88  0.38, P 
0.05) and on the ability of dexamethasone to suppress IL-8
release (Fig. 4 A). There was also a small effect on the dex-
amethasone IC50 (6.6  0.4 versus 1.0  0.2 nM, P 
0.05). However, theophylline restored dexamethasone sen-
sitivity in IL-1	  H2O2–stimulated cells (Fig. 4 A) and re-
duced IL-8 expression down to levels seen with IL-1	 
Dex–stimulated cells. There was also a marked shift in the
dexamethasone IC50 (4.9  0.44 nM versus  1 M, P 
0.01). In AM from smokers, the enhancing effect of the-
ophylline was completely blocked by the addition of the
HDAC inhibitor trichostatin A (Fig. 4 C). Immunoprecip-
itation of HDACs 1 and 2 indicated that the activity of
both of these enzymes was increased by theophylline in
U937 cells (Fig. 4 D) and also in BAL macrophages from
smokers (Fig. 4 E).
We have shown that AM from smokers and patients with
COPD show increased release of the neutrophil-selective
chemokine IL-8 and the proinflammatory cytokine TNF-,
which are associated with enhanced activation of the tran-
scription factor NF-B. We have also shown that the ex-
pression and activity of the corepressor protein HDAC,
which inhibits NF-B, is reduced in AM from smokers and
that this is significantly further reduced in COPD patients.
This reduction in HDAC activity was reversed by the-
ophylline in AM from both smokers and patients with
COPD. Furthermore, theophylline enhanced the ability of
dexamethasone to suppress LPS-induced IL-8 release in
macrophages and restored dexamethasone sensitivity. In
U937 cells, oxidative stress reduced HDAC activity, and we
hypothesize that oxidative stress is the causative agent for
the reduced HDAC activity seen primary macrophages
from smokers and that this leads to enhanced inflammatory
gene transcription and a reduced response to glucocorti-
coids. Under these conditions, where we see a 70% reduc-
tion in HDAC activity, the sensitivity to glucocorticoids is
reduced as well as the maximal response resulting in a
marked 2–3-log shift in the concentration response curve.
Achieving a 100–1,000-fold difference in glucocorticoid
dosage in patients is difficult due to side effects and the re-
duced maximal response would still result in less suppression
of inflammatory indices. Theophylline restored the antiin-
Figure 3. Effect of theophylline effect on HDAC activity and dexametha-
sone sensitivity in AM. (A) Nuclear extracts obtained from AM of heavy
smokers and patients with COPD were incubated with theophylline (10
5
and 10
6 M) for 20 min, and HDAC activity was measured. **P  0.01,
n  3. (B) Effect of theophylline (Theo; 10
6 M) and dexamethasone
(Dex; 10
6 M) alone and in combination on LPS-stimulated IL-8 release
from AM obtained from COPD patients cultured overnight. #P  0.05
versus LPS; ##P  0.01 versus LPS; *P  0.05 versus LPS plus dexametha-
sone (n  6).
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flammatory effects of glucocorticoids by increasing HDAC
activity an effect that was completely blocked by the HDAC
inhibitor trichostatin A in AM from smokers.
Macrophages are critical cells in COPD and contribute
to the airway inflammation in smokers and COPD patients
by secreting neutrophil and lymphocyte chemotactic fac-
tors, proteases, and reactive oxygen species (5). In this
study, we found significantly higher numbers of AM and
neutrophils in BAL fluid of smokers and COPD patients, in
agreement with previous studies (3). We found increased
nuclear localization of p65, indicating NF-B activation in
AM of smokers and to an even greater extent in COPD
patients, confirming previous reports (14). The presence of
nuclear p65 and enhanced basal and enhanced IL-8 release
suggests that these cells were in a more active state than
those obtained from normal subjects. In addition, an indi-
rect sign of oxidative stress was the increased concentration
of glutathione (GSH) in BAL fluid. Oxidative stress has
been correlated previously with a defective thiol status in
alveolar macrophages, with an increase of GSH in epithelial
lining fluid (15), and is an important regulator of IL-8 gene
expression (16).
IL-8 and TNF are important inflammatory mediators
in COPD, and both mediators are increased in sputum
from patients with COPD (4). Neither inhaled nor oral
glucocorticoids had any suppressive effect on their regula-
tion in COPD patients (5). In our study, AM from smokers
and COPD patients were activated and relatively resistant
to the suppressive actions of glucocorticoids confirming
previous data previously. We have reported previously that
cytokine expression is enhanced and glucocorticoid effec-
tiveness is reduced in alveolar macrophages from normal
smokers and that this is correlated with a decreased HDAC
activity and, in particular, reduced expression of HDAC2
(17). We have also shown previously that maximal repres-
sive actions of glucocorticoids require recruitment of
HDAC2 to a p65-HAT complex (11). In the present
study, with a different population of smokers, we confirm
that HDAC activity is reduced and for the first time show
an even greater reduction in HDAC activity and HDAC2
expression in AM from COPD patients. In this study, 6 of
19 COPD subjects were excluded due to a failure to obtain
sufficient viable AM. Although we obtained a large num-
ber of AM from almost of all patients, in some of the more
severe patients all, or most, of the AM died. This would
suggest that there may be a bias toward a less severe group
of patients. In preliminary studies we have found that the
reduction in HDAC activity in the peripheral lung of
COPD patients correlated with increasing stage of disease
(unpublished data). This suggests that if we were able to
obtain AM consistently from these more severe patients
that there may be a greater effect of theophylline on the pa-
rameters measured here.
In the macrophage-like U937 cells, we were able to
Figure 4. Theophylline effect
on HDAC activity and steroid
sensitivity in oxidant-stressed
U937 cells and AM. (A) Effect of
theophylline (Theo, 10
6 M) and
dexamethasone (Dex; 10
8 M)
alone and in combination on
IL-1	 (1 ng/ml) and IL-1	 
hydrogen peroxide (H2O2; 100
M)–stimulated IL-8 release
from U937 cells. Theophylline
(10
6 M) enhanced sensitivity
compared with cells treated with
IL-1	 and H2O2. *P  0.05 versus
IL-1	; #P  0.01 versus IL-1	  H2O2· (B) Effect of theophylline (Theo; 10
6 M) on cigarette
smoke extract (CSE; 0.15 dilution)–induced reduction in HDAC activity. ***P  0.001 versus con-
trol; ##P  0.01 versus CSE in U937 cells. (C) Effect of theophylline (Theo; 10
5 M) and dexa-
methasone (Dex; 10
10 M) alone and in combination on LPS (10 ng/ml)-induced IL-8 release from
AM obtained from smokers. Theophylline enhanced Dex sensitivity, an effect that was blocked by
addition of the HDAC inhibitor trichostatin A (TSA; 10 ng/ml). *P  0.05 versus LPS, n  3.
(D) Specific HDAC isoforms were immunoprecipitated from U937 cells and incubated with the-
ophylline (10
6 M) for 20 min before HDAC activity was measured. ***P  0.001 (n  4). (E) Spe-
cific HDAC isoforms were immunoprecipitated from AM from smokers and incubated with the-
ophylline (10
6 M) for 20 min before HDAC activity was measured. n  3.
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demonstrate that oxidative stress (H2O2) markedly en-
hanced the release of IL-8 and reduced the antiinflamma-
tory action of glucocorticoids, thus mimicking closely the
behavior of COPD macrophages. Moreover, these abnor-
malities were completely reversed by low concentrations of
theophylline. Trichostatin A inhibited the action of the-
ophylline, confirming that it was mediated via HDAC acti-
vation rather than some other mechanism. It is of interest
that in patients with mild asthma who are normally steroid
sensitive, a complete resistance the antiinflammatory action
of inhaled and oral glucocorticoids is observed in smokers
(18, 19), and this may be explained by a similar mechanism.
We have shown recently (20) that oxidative stress can in-
duce HDAC nitration and that this correlates with reduced
HDAC activity possibly as a result of targeting for proteo-
somal degradation. Furthermore, in preliminary data we
have shown that HDAC2 isolated from macrophages from
COPD patients has a greater level of tyrosine nitration of
HDAC2 than normal subjects (21). We speculate, there-
fore, that one possible mechanism that accounts for the in-
hibitory effect of oxidative stress on HDAC2 activity is ni-
tration and inactivation/degradation of the enzyme.
In an attempt to reverse the reduced HDAC activity, we
explored the activity of theophylline as a HDAC stimulator
in COPD (12). Theophylline activates HDAC activity and
therefore suppresses the expression of inflammatory genes
through a mechanism independent of cAMP modulation
(12). This would explain the antiinflammatory effects of
theophylline observed previously in asthma (11) and more
recently in COPD (11). The effect is distinct from that of
glucocorticoids, as there appears to be a relatively direct ac-
tivation of HDAC, whereas glucocorticoid effects are due
to recruitment of HDAC2 to the active site of transcription
(8). In the present study, we saw a marked (over sixfold) in-
crease in the depressed HDAC activity in COPD macro-
phages. Enhanced HDAC activity alone is not effective in
suppressing inflammatory gene transcription unless it is re-
cruited to the active proinflammatory transcriptional com-
plex by the glucocorticoid receptor. This would explain the
relative lack of effect of theophylline alone in suppressing
IL-8 release and the potentiation of this effect when the cells
are pretreated with dexamethasone. This effect is seen at
therapeutic concentrations of theophylline (10
6–10
5 M)
and is not mediated by either phosphodiesterase inhibition
or by adenosine receptor antagonism (12). Theophylline
enhances HDAC1 and HDAC2 activity in U937 cells and
in AM from smokers, and this may play a role in the regula-
tion of NF-B–induced inflammatory gene expression (8,
22, 23). However, HDAC2 is the relevant isoform for the
enhancement of steroid responsiveness.
In conclusion, we have shown an important explanation
to the glucocorticoid-resistant inflammatory process ob-
served in COPD (9). Reduction of HDAC activity may be
responsible for the enhanced inflammatory gene transcrip-
tion, and this is not directly related to an increase in NF-B
activation, but as a direct effect of oxidative stress. Low
dose theophylline may “unlock” the glucocorticoid resis-
tance of COPD and potentiate its suppressive effects. This
suggests that theophylline may restore the antiinflammatory
effect of glucocorticoids and thus control the underlying
disease process in COPD. This needs to be confirmed in
clinical studies in COPD patients, but theophylline might
provide a relatively inexpensive way of managing this com-
mon and globally increasing disease.
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